Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study

Aim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Met...

Full description

Bibliographic Details
Main Authors: Subhash Kumar Wangnoo, Samit Ghosal, Shahid Akhtar, Raman Shetty, Sudhir Tripathi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=Wangnoo
_version_ 1819181472869777408
author Subhash Kumar Wangnoo
Samit Ghosal
Shahid Akhtar
Raman Shetty
Sudhir Tripathi
author_facet Subhash Kumar Wangnoo
Samit Ghosal
Shahid Akhtar
Raman Shetty
Sudhir Tripathi
author_sort Subhash Kumar Wangnoo
collection DOAJ
description Aim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Methods : Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. Results : A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A 1c (HbA 1c ) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA 1c levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. Conclusion: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients.
first_indexed 2024-12-22T22:30:47Z
format Article
id doaj.art-54c28355279b40dc88032ec5468e7998
institution Directory Open Access Journal
issn 2230-8210
2230-9500
language English
last_indexed 2024-12-22T22:30:47Z
publishDate 2014-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Endocrinology and Metabolism
spelling doaj.art-54c28355279b40dc88032ec5468e79982022-12-21T18:10:26ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002014-01-0118571572010.4103/2230-8210.139239Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve studySubhash Kumar WangnooSamit GhosalShahid AkhtarRaman ShettySudhir TripathiAim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Methods : Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. Results : A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A 1c (HbA 1c ) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA 1c levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. Conclusion: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients.http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=WangnooGlargineIndiainsulin detemirneutral protamine Hagedorn insulintype 2 diabetes
spellingShingle Subhash Kumar Wangnoo
Samit Ghosal
Shahid Akhtar
Raman Shetty
Sudhir Tripathi
Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
Indian Journal of Endocrinology and Metabolism
Glargine
India
insulin detemir
neutral protamine Hagedorn insulin
type 2 diabetes
title Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
title_full Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
title_fullStr Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
title_full_unstemmed Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
title_short Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
title_sort clinical experience of switching from glargine or neutral protamine hagedorn insulin to insulin detemir in type 2 diabetes observations from the indian cohort in the a 1 chieve study
topic Glargine
India
insulin detemir
neutral protamine Hagedorn insulin
type 2 diabetes
url http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=Wangnoo
work_keys_str_mv AT subhashkumarwangnoo clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT samitghosal clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT shahidakhtar clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT ramanshetty clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy
AT sudhirtripathi clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy